AP-1 and colorectal cancer

Inflammopharmacology

Volumn 13, Issue 1-3, 2005, Pages 113-125

  Ashida, Reiko ^a   Tominaga, Kazunari ^a   Sasaki, Eiji ^a   Watanabe, Toshio ^a   Fujiwara, Yasuhiro ^a   Oshitani, Nobuhide ^a   Higuchi, Kazuhide ^a   Mitsuyama, Shokei ^b   Iwao, Hiroshi ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Activator protein 1 (AP 1); c Jun; Colorectal cancer; Gene therapy

Indexed keywords

ADENOVIRUS VECTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; PROTEIN C JUN; PROTEIN P27; PROTEIN P53; PROTEIN TAM67; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC ANALYSIS; HUMAN; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE THERAPY; HUMANS; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1;

EID: 27744561738     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856005774423935     Document Type: Review

References (66)

1. Angel, P., Imagawa, M., Chiu, R., et al. (1987). Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor, Cell 49, 729-739.
2. Angel, P. and Karin, M. (1991). The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation, Biochim. Biophys. Acta 1072, 129-157.
3. Barnes, P. J. and Adcock, I. M. (1998). Transcription factors and asthma, Eur. Respir. J. 12, 221-234.
4. Binetruy, B., Smeal, T. and Karin, M. (1991). Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain, Nature 351, 122-127.
5. Brown, P. H., Alani, R., Preis, L. H., Szabo, E. and Birrer, M. J. (1993). Suppression of oncogene-induced transformation by a deletion mutant of c-Jun, Oncogene 8, 877-886.
6. Brown, P. H., Chen, T. K. and Birrer, M. J. (1994). Mechanism of action of a dominant-negative mutant of c-Jun, Oncogene 9, 791-799.
7. Brusselbach, S., Mohle-Steinlein, U., Wang, Z. Q., et al. (1995). Cell proliferation and cell cycle progression are not impaired in fibroblasts and ES cells lacking c-Fos, Oncogene 10, 79-86.
8. Chiu, R., Angel, P. and Karin, M. (1989). Jun-B differs in its biological properties from, and is a negative regulator of c-Jun, Cell 59, 979-986.
9. Chung-Faye, G. A., Kerr, D. J., Young, L. S., et al. (2000). Gene therapy strategies for colon cancer, Mol. Med. Today 6, 82-87.
10. Debruyne, P. R., Bruyneel, E. A., Li, X., et al. (2001). The role of bile acids in carcinogenesis, Mutation Res. 480-481, 359-369.
11. Deng, T. and Karin, M. (1994). c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK, Nature 371, 171-175.
12. Eferl, R., Sibilia, M., Hilberg, F., et al. (1999). Functions of c-Jun in liver and heart development, J. Cell. Biol. 145, 1049-1061.
13. Estus, S., Zaks, W. J., Freeman, R. S., et al. (1994). Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis, J. Cell. Biol. 127, 1717-1727.
14. Frantz, S., Fraccarollo, D., Wagner, H., et al. (2003). Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure, Cardiovasc. Res. 57, 749-756.
15. Grady, W. M. (2004). Genomic instability and colon cancer, Cancer Metastasis Rev. 23, 11-27.
16. Grau, R., Iniguez, M. A. and Fresno, M. (2004). Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism, Cancer Res. 64, 5162-5171.
17. Gryfe, R., Swallow, C., Bapat, B., Redston, M., Gallinger, S. and Couture, J. (1997). Molecular biology of colorectal cancer, Curr. Probl. Cancer 21, 233-300.
18. Ham, J., Babij, C., Whitfield, J., et al. (1995). A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death, Neuron 14, 927-939.
19. Hartl, M., Bader, A. G. and Bister, K. (2003). Molecular targets of the oncogenic transcription factor jun, Curr. Cancer Drug Targets 3, 41-55.
20. Jochum, W., Passegue, E. and Wagner, E. F. (2001). AP-1 in mouse development and tumorigenesis, Oncogene 20, 2401-2412.
21. Johnson, R. S., van Lingen, B., Papaioannou, V. E., et al. (1993). A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture, Genes. Dev. 7, 1309-1317.
22. Kallunki, T., Deng, T., Hibi, M., et al. (1996). c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions, Cell 87, 929-939.
23. Kardassis, D., Papakosta, P., Pardali, K., et al. (1999). c-Jun transactivates the promoter of the human p21(WAF1/Cip1). gene by acting as a superactivator of the ubiquitous transcription factor Sp1, J. Biol. Chem. 274, 29572-29581.
24. Kikkawa, R., Koya, D. and Haneda, M. (2003). Progression of diabetic nephropathy, Am. J. Kidney Dis. 41, S19-21.
25. Kolbus, A., Herr, I., Schreiber, M., et al. (2000). c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents, Mol. Cell Biol. 20, 575-582.
26. Kovary, K. and Bravo, R. (1991). The jun and fos protein families are both required for cell cycle progression in fibroblasts, Mol. Cell Biol. 11, 4466-4472.
27. Lamph, W. W., Wamsley, P., Sassone-Corsi, P., et al. (1988). Induction of proto-oncogene JUN/AP-1 by serum and TPA, Nature 334, 629-631.
28. Laurent-Puig, P., Blons, H. and Cugnenc, P. H. (1999). Sequence of molecular genetic events in colorectal tumorigenesis, Eur. J. Cancer Prev. 8 (Suppl. 1), S39-S47.
29. Li, J. J., Cao, Y., Young, M. R., et al. (2000). Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes, Mol. Carcinog. 29, 159-169.
30. Li, J. J., Westergaard, C., Ghosh, P., et al. (1997). Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response, Cancer Res. 57, 3569-3576.
31. Licato, L. L., Keku, T. O., Wurzelmann, J. I., et al. (1997). In vivo activation of mitogen-activated protein kinases in rat intestinal neoplasia, Gastroenterology 113, 1589-1598.
32. Ludes-Meyers, J. H., Liu, Y., Munoz-Medellin, D., et al. (2001). AP-1 blockade inhibits the growth of normal and malignant breast cells, Oncogene 20, 2771-2780.
33. Maki, Y., Bos, T. J., Davis, C., et al. (1987). Avian sarcoma virus 17 carries the jun oncogene, Proc. Natl. Acad. Sci. USA 84, 2848-2852.
34. Mann, B., Gelos, M., Siedow, A., et al. (1999). Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas, Proc. Natl. Acad. Sci. USA 96, 1603-1608.
35. Midgley, R. and Kerr, D. (1999). Colorectal cancer, Lancet 353, 391-399.
36. Naumann, M., Wessler, S., Bartsch, C., et al. (1999). Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island, J. Biol. Chem. 274, 31655-31662.
37. Nordling, M. M., Glinghammar, B., Karlsson, P. C., et al. (2003). Effects on cell proliferation, activator protein-1 and genotoxicity by fecal water from patients with colorectal adenomas, Scand. J. Gastroenterol. 38, 549-555.
38. Ozanne, B. W., McGarry, L., Spence, H. J., et al. (2000). Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme, Eur. J. Cancer 36, 1640-1648.
39. Palmer, D. H., Chen, M. J. and Kerr, D. J. (2002). Gene therapy for colorectal cancer, Br. Med. Bull. 64, 201-225.
40. Pennypacker, K. R., Kassed, C. A., Eidizadeh, S., et al. (2000). Brain injury: prolonged induction of transcription factors, Acta Neurobiol. Exp. 60, 515-530.
41. Potapova, O., Basu, S., Mercola, D., et al. (2001). Protective role for c-Jun in the cellular response to DNA damage, J. Biol. Chem. 276, 28546-28553.
42. Quantin, B. and Breathnach, R. (1988). Epidermal growth factor stimulates transcription of the c-jun proto-oncogene in rat fibroblasts, Nature 334, 538-539.
43. Rowinsky, E. K., Windle, J. J. and Von Hoff, D. D. (1999). Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development, J. Clin. Oncol. 17, 3631-3652.
44. Schreiber, M., Rolbus, A., Piu, F., et al. (1999). Control of cell cycle progression by c-Jun is p53 dependent, Genes Dev. 13, 607-619.
45. Shaulian, E. and Karin, M. (2001). AP-1 in cell proliferation and survival, Oncogene 20, 2390-2400.
46. Shaulian, E. and Karin, M. (2002). AP-1 as a regulator of cell life and death, Nature Cell Biol. 4, E131-E136.
47. Shaulian, E., Schreiber, M., Piu, F., et al. (2000). The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest, Cell 103, 897-907.
48. Shin, S. C. and Claffey, K. P. (2001). Role of AP-1 and HIF-1 transcription factors in TGF-beta activation of VEGF expression, Growth Factors 19, 19-34.
49. Shimizu, N., Yoshiyama, M., Omura, T., et al. (1998). Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats, Cardiovasc. Res. 38, 116-124.
50. Smith, L. M., Wise, S. C., Hendricks, D. T., et al. (1999). cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype, Oncogene 18, 6063-6070.
51. Smith, M. J. and Prochownik, E. V. (1992). Inhibition of c-jun causes reversible proliferative arrest and withdrawal from the cell cycle, Blood 79, 2107-2115.
52. Stein, B., Baldwin Jr., A. S., Ballard, D. W., et al. (1993). Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function, EMBO J. 12, 3879-3891.
53. Suto, R., Tominaga, K., Mizuguchi, H., et al. (2004). Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer, Gene Ther. 11, 187-193.
54. Thanos, D. and Maniatis, T. (1995). NF-kappa B: a lesson in family values, Cell 80, 529-532.
55. Tournier, C., Hess, P., Yang, D. D., et al. (2000). Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway, Science 288, 870-874.
56. Van Straaten, F., Muller, R., Curran, T., et al. (1983). Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein, Proc. Natl. Acad. Sci.USA 80, 3183-3187.
57. Wang, C. H., Tsao, Y. P., Chen, H. J., et al. (2000a). Transcriptional repression of p21((Waf1/Cip1/Sdi1)) gene by c-jun through Sp1 site, Biochem. Biophys. Res. Commun. 270, 303-310.
58. Wang, H., Birkenbach, M. and Hart, J. (2000b). Expression of Jun family members in human colorectal adenocarcinoma, Carcinogenesis 21, 1313-1317.
59. World Health Organization (2003). The world health report. WHO, Geneva.
60. Wisdom, R., Johnson, R. S. and Moore, C. (1999). c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms, EMBO J. 18, 188-197.
61. Yamamoto, H., Itoh, F., Senota, A., et al. (1995). Expression of matrix metalloproteinase matrilysin (MMP-7) was induced by activated Ki-ras via AP-1 activation in SW1417 colon cancer cells, J. Clin. Lab. Anal. 9, 297-301.
62. Yao, K. S., Xanthoudakis, S., Curran, T., et al. (1994). Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia, Mol. Cell Biol. 14, 5997-6003.
63. Yasumoto, H., Kim, S., Zhan, Y., et al. (2001). Dominant negative c-jun gene transfer inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in rats, Gene Ther. 8, 1682-1689.
64. Young, M. R., Yang, H. S. and Colburn, N. H. (2003). Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4, Trends Mol. Med. 9, 36-41.
65. Zhan, Y., Kim, S., Yasumoto, H., et al. (2002). Effects of dominant-negative c-Jun on platelet-derived growth factor-induced vascular smooth muscle cell proliferation, Arterioscler. Thromb. Vasc. Biol. 22, 82-88.
66. Zwacka, R. M. and Dunlop, M. G. (1998). Gene therapy for colon cancer, Hematol. Oncol. Clin. North Am. 12, 595-615.